Introduction: 188Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for treatment of osteoblastic bone metastases. It is known that the presence of carrier (non-radioactive rhenium as ammonium perrhenate) in the reaction mixture during labeling is a prerequisite for adequate bone affinity, but little is known about the optimal carrier concentration. Methods: We investigated the influence of carrier concentration in the formulation on the radiochemical purity, in-vitro hydroxyapatite affinity and the in-vivo bone accumulation of 188Rhenium-HEDP in mice. Results: The carrier concentration influenced hydroxyapatite binding in-vitro as well as bone accumulation in-vivo. Variation in hydroxyapatite binding with various ...
The purpose of this study is to prepare 99mTc-HEDTMP [N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri (m...
[186gRe]Re-HEDP is a radiopharmaceutical used for pain palliation in bone metastases from various pr...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Introduction: 188Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for tr...
INTRODUCTION: (188)Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for ...
The nuclear properties of 186gRe make it a useful agent for radionuclide therapy and imaging. The co...
Rhemium-186-1-hydroxyethylidene-1,1-diphosphonate ( 186Re-HEDP) has been used for the palliation of ...
Item does not contain fulltextTherapeutic phosphonate-based radiopharmaceuticals radiolabeled with b...
ABSTRACT: Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphon...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Introduction Rhenium-188-HEDP (188Re-HEDP) is a therapeutic radiopharmaceutical for treatment of ost...
Bone-seeking therapeutic radiopharmaceuticals are utilized on the basis of the radionuclide?s partic...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of hi...
The purpose of this study is to prepare 99mTc-HEDTMP [N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri (m...
[186gRe]Re-HEDP is a radiopharmaceutical used for pain palliation in bone metastases from various pr...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Introduction: 188Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for tr...
INTRODUCTION: (188)Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for ...
The nuclear properties of 186gRe make it a useful agent for radionuclide therapy and imaging. The co...
Rhemium-186-1-hydroxyethylidene-1,1-diphosphonate ( 186Re-HEDP) has been used for the palliation of ...
Item does not contain fulltextTherapeutic phosphonate-based radiopharmaceuticals radiolabeled with b...
ABSTRACT: Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphon...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Introduction Rhenium-188-HEDP (188Re-HEDP) is a therapeutic radiopharmaceutical for treatment of ost...
Bone-seeking therapeutic radiopharmaceuticals are utilized on the basis of the radionuclide?s partic...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of hi...
The purpose of this study is to prepare 99mTc-HEDTMP [N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri (m...
[186gRe]Re-HEDP is a radiopharmaceutical used for pain palliation in bone metastases from various pr...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...